Latest From Celltrion Inc.
In addition to our daily in-depth coverage of key events relating to the coronavirus pandemic, we’re bringing you a periodic round-up of other significant developments.
Coronavirus Update: South Korea's Celltrion Progresses Antibody, Yancopoulos: 'The World Is Counting On Us'
Regeneron's head of R&D George Yancopoulos delivers some stirring words about the need to unify against the global threat posed by COVID-19.
Celltrion unveils emergency plans to deal with the COVID-19 situation in South Korea by speeding up development of a potential therapeutic antibody and rapid, accurate testing kit without considering economic returns.
Teva and Celltrion have launched their Herzuma trastuzumab biosimilar in the US at a 10% discount to the Herceptin brand. The discount matches that offered for their Truxima rituximab biosimilar and compares to steeper discounts offered by competing biosimilars.
- Large Molecule
- Contract Research, Toxicology Testing-CRO
- Generic Drugs
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- Musculoskeletal & Connective Tissue Disorders
- Respiratory, Pulmonary
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- Celltrion Inc.
- Senior Management
- Hyoung-Ki Kim, Co-CEO
- Contact Info
Phone: (82) 32 850 5000
Incheon City, 406-840
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.